Story perspectives

Frustration Grows as NHS Denies Life-Saving Drug Access

10/23/2025

43 10

Summary

Story summary

Darren Ashton-Lake, 32, suffers from Friedreich's Ataxia and is frustrated that the NHS will not fund omaveloxolone, a drug that could slow his condition.
Biogen withdrew its application for NHS approval due to the drug's annual cost of £298,500.
Ashton-Lake emphasizes that access to necessary medications is vital for hope and quality of life.
While some patients report benefits from the drug, NICE states it does not meet criteria for specialized review.
The UK Department of Health aims to improve access to innovative medicines by 2030.

1 of 1

Story summary

Darren Ashton-Lake, 32, suffers from Friedreich's Ataxia and is frustrated that the NHS will not fund omaveloxolone, a drug that could slow his condition.
Biogen withdrew its application for NHS approval due to the drug's annual cost of £298,500.
Ashton-Lake emphasizes that access to necessary medications is vital for hope and quality of life.
While some patients report benefits from the drug, NICE states it does not meet criteria for specialized review.
The UK Department of Health aims to improve access to innovative medicines by 2030.